Emerging therapeutic targets in schwannomas and other merlin-deficient tumors
Sylwia Ammoun1, C Oliver Hanemann
1Clinical Neurobiology, Peninsula College of Medicine and Dentistry, University of Plymouth, The John Bull Building, Tamar Science Park, Research Way, Plymouth PL6 8BU, UK.
Abstract:
Deficiency of the tumor suppressor protein merlin leads to the development of benign tumors of the nervous system such as schwannomas, ependymomas and meningiomas. These tumors can occur spontaneously or as part of a tumor predisposition syndrome called neurofibromatosis type 2 (NF2), which involves multiple tumors. Schwannomas are the hallmark tumors of NF2 and are the most frequent and well-characterized of the merlin-deficient tumors. Surgery or radiotherapy are used to treat single tumors and can leave the patient with substantial morbidity. Limitations of other treatment options for merlin-deficient tumors, such as the lack of effectiveness of chemotherapy, have led to an urgent requirement for new pharmaceutical therapies. Merlin-deficient tumors are genetically well-defined, which allows rational testing of new molecular therapies that have been developed and successfully used to treat various cancers in the past few years. This Review centers on four key families of receptor tyrosine kinases-the ErbB family, platelet-derived growth factor receptor β, insulin-like growth factor 1 receptor, and vascular endothelial growth factor receptors-focusing on their role in schwannoma pathobiology and the therapeutic potential of targeting these receptors and their downstream signaling pathways.
Insights
Deficiency in merlin protein causes nervous system tumors like schwannomas, often seen in neurofibromatosis type 2 (NF2). Targeting specific receptor tyrosine kinases offers promising new therapeutic strategies for these merlin-deficient tumors.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- Merlin protein deficiency is linked to benign nervous system tumors, including schwannomas, ependymomas, and meningiomas.
- Schwannomas are characteristic tumors in neurofibromatosis type 2 (NF2), a genetic disorder causing multiple tumors.
- Current treatments for these tumors, such as surgery and radiotherapy, can lead to significant patient morbidity.
Purpose of the Study:
- To review the role of receptor tyrosine kinases in the pathobiology of merlin-deficient schwannomas.
- To explore the therapeutic potential of targeting these receptor tyrosine kinases and their downstream signaling pathways.
- To highlight the need for novel pharmaceutical therapies due to the limitations of existing treatments for merlin-deficient tumors.
Main Methods:
- Review of scientific literature focusing on merlin-deficient tumors, specifically schwannomas.
- Analysis of the involvement of four key receptor tyrosine kinase families: ErbB, platelet-derived growth factor receptor β, insulin-like growth factor 1 receptor, and vascular endothelial growth factor receptors.
- Examination of the downstream signaling pathways associated with these receptor tyrosine kinases.
Main Results:
- Merlin-deficient tumors are genetically well-defined, facilitating the rational development of targeted therapies.
- Specific receptor tyrosine kinases play a crucial role in the development and progression of schwannomas.
- Targeting these receptor tyrosine kinases and their signaling pathways presents a viable therapeutic strategy.
Conclusions:
- Novel pharmaceutical therapies targeting receptor tyrosine kinases are urgently needed for merlin-deficient tumors.
- Understanding the molecular mechanisms driving schwannoma development is key to developing effective treatments.
- Targeted therapies offer a promising avenue for improving outcomes in patients with NF2 and other merlin-deficient tumors.
